Amgen Stock Rating Maintained at Neutral by Cantor Fitzgerald
Cantor Fitzgerald has maintained its Neutral rating on Amgen Inc. with a price target of $400, even as the stock currently trades at $403. The firm highlights Amgen’s solid commercial execution, noting a 9.1% revenue growth over the last twelve months to $38.1 billion, alongside a robust gross profit margin of 71.9%. The P/E ratio stands at 25.1, while the PEG ratio is 0.79.
The report also mentioned adjusted expectations for Lp(a) following the HORIZON results and positive data from Sjogren’s trials. Cantor Fitzgerald observed that Amgen has regained its status as a consensus long position among investors. The firm also noted a relatively quiet catalyst calendar for the company through year-end 2026.
InvestingPro has rated Amgen’s financial health as “GREAT” and suggests the stock is undervalued based on its Fair Value assessment. The platform offers deeper insights through Pro Research Reports for Amgen and other US equities.
In other recent developments, Amgen reported successful results from its OASIZ 301 Phase 3 trial for dazodalibep, targeting moderate-to-severe systemic Sjögren’s disease. The trial met its primary endpoint, showing significant improvements in disease activity. Following these results, Oppenheimer reiterated its Outperform rating with a $450 price target, while Jefferies raised its target to $410. Canaccord Genuity and UBS also adjusted their ratings, reflecting a mix of optimism and caution among analysts.